Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
![Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022522320325629-fx1.jpg)
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect
![Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01659-0/MediaObjects/12325_2021_1659_Fig3_HTML.png)
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
KAZIA PRESENTS FURTHER PAXALISIB AND CANTRIXIL DATA AT AACR, REINFORCING POSITIVE EFFICACY SIGNALS FOR BOTH DRUGS
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
![Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online](https://ascpt.onlinelibrary.wiley.com/cms/asset/f103bc07-2ef1-4ae5-8bba-aeee888ec782/cpt1956-fig-0006-m.jpg)
Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online
Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Netw
![Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40425-017-0276-8/MediaObjects/40425_2017_276_Fig2_HTML.gif)
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
![Response rates Overall response rate and depth of response according to... | Download Scientific Diagram Response rates Overall response rate and depth of response according to... | Download Scientific Diagram](https://www.researchgate.net/publication/341590087/figure/fig3/AS:958461890281480@1605526530128/Response-rates-Overall-response-rate-and-depth-of-response-according-to-renal-function-in.png)
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
![Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40425-017-0276-8/MediaObjects/40425_2017_276_Fig1_HTML.gif)
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
![Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825817307709-gr2.jpg)
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
![Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study](https://www.frontiersin.org/files/Articles/990224/fimmu-13-990224-HTML/image_m/fimmu-13-990224-t002.jpg)
Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
![Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online](https://ascpt.onlinelibrary.wiley.com/cms/asset/49014501-e4df-472b-ba20-5d9070a5e56d/cpt1956-fig-0005-m.jpg)
Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online
![Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01659-0/MediaObjects/12325_2021_1659_Fig1_HTML.png)